Corticosteroids
| Zeile 14: | Zeile 14: | ||
{{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} | {{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} | ||
{{tp|p=C7189003|t=2020. Glukokortikoide und Covid-19 |pdf=|usr=}} | {{tp|p=C7189003|t=2020. Glukokortikoide und Covid-19 |pdf=|usr=}} | ||
| + | {{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=007}} | ||
| + | {{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=007}} | ||
| + | {{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | {{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=007}} | ||
| + | {{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=007}} | ||
| + | {{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=007}} | ||
| + | |||
| + | {{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=007}} | ||
Version vom 23. Juni 2020, 14:02 Uhr
32149773 ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial
32272008 2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2
32341100 2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
32321620 ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword
32283153 ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1
32122468 2020. On the use of corticosteroids for 2019-nCoV pneumonia
32043983 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
32372026 ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
32341331 2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
32133159 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
32266987 2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
32164084 2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia
32296012 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
C7189003 2020. Glukokortikoide und Covid-19
32475851 2020. COVID-19: Stay Cool toward Corticosteroids.
32409522 2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.
32427279 2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.
32470160 2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.
32441786 2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.
32034899 2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].
32496422 2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.
